How well does Vosevi(Sofosbuvir/Velpatasvir/Voxilaprevir) work?

A summary of the clinical trial results demonstrating the drug's effectiveness.

Clinical Outcomes

The efficacy of VOSEVI was established in two Phase 3 clinical trials (POLARIS-1 and POLARIS-4) in DAA-experienced subjects. In these studies, 12 weeks of treatment with VOSEVI resulted in high rates of sustained virologic response (SVR12), achieving 96% SVR12 in NS5A inhibitor-experienced patients and 97% in those without prior NS5A inhibitor exposure in the respective trials, demonstrating its effectiveness as a retreatment option.